.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB14_CepeginterferonAlfa2b.CepeginterferonAlfa2b .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB14_CepeginterferonAlfa2b.CepeginterferonAlfa2b| name: | CepeginterferonAlfa2b |
| ATC code: | L03AB14 | route: |
| n-compartments | 0 |
Cepeginterferon alfa-2b is a long-acting, pegylated recombinant interferon alfa-2b designed to improve pharmacokinetic properties such as half-life and reduced dosing frequency compared to conventional interferon-alpha. The drug is primarily aimed for use in chronic hepatitis (such as hepatitis B or C), with potential for use in myeloproliferative neoplasms. As of 2024, cepeginterferon alfa-2b is not widely approved or marketed globally, though related pegylated forms are approved for some indications.
No published pharmacokinetic models or parameter values could be identified in the peer-reviewed literature for cepeginterferon alfa-2b as of June 2024. Thus, PK parameters are not directly referenced or reported here.